Immunotherapy before radiation for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy drug called toripalimab, given before, during, and after standard radiation and chemotherapy for esophageal cancer that hasn't spread. The goal is to see if adding this drug can improve outcomes for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with esophageal squamous cell carcinoma that is stage II-IVA and hasn't been treated yet.
- You are in generally good health (able to care for yourself and up and about more than 50% of waking hours).
- You have not had radiation to the chest or immunotherapy before.
- You do not have an autoimmune disease or take high-dose steroids.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares surgery versus a strong combination of chemotherapy and radiation for people with esophageal squamous cell carcinoma that has been treated first with immunotherapy. It aims to find which approach leads to better outcomes after the initial immunotherapy and chemotherapy.
This trial tests if giving chemotherapy and radiation before surgery, followed by immunotherapy, can improve outcomes for people with a specific type of esophageal cancer that can be surgically removed.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy before surgery for esophageal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests a new combination of treatments for people with advanced esophageal cancer that can't be removed by surgery. It uses a targeted therapy called surufatinib along with chemo-immunotherapy and radiation to see if it can shrink the tumor before further treatment.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.